MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, announced today that Matt Rainville has been appointed chief commercial officer. In this role, Rainville will lead the growth of the fully commercial Bigfoot Unity® Diabetes Management Program as Bigfoot expands access to diabetes clinics and health systems in 2022 and beyond.
Mr. Rainville is a veteran commercial executive in the pharmaceutical and medical technology industry with extensive sales, operations, and marketing experience in the global diabetes market. He previously served as Insulet Corporation’s (NASDAQ: PODD) vice president and general manager of global Type 2 markets, where he led the company’s Omnipod Type 2 franchise and helped to expand access to insulin pumps for people with diabetes. Prior to Insulet, Rainville spent 13 years with Eli Lilly and Company (NYSE: LLY), where he held integral leadership roles in sales, training and development, marketing, operations, and market access - contributing to the successful launch of nine diabetes products globally.
“Hiring a chief commercial officer is a crucial step for our business as we expand access to our Bigfoot Unity System and further develop our pipeline,” said Jeffrey Brewer, CEO of Bigfoot Biomedical. “Matt has a proven track record developing effective commercial and market access strategies that have driven adoption of technologies for people with diabetes. His experience will serve us well as we continue to grow our presence in the commercial marketplace. We are thrilled to welcome Matt to the Bigfoot leadership team and are eager to harness his passion for improving care for people with diabetes.”
Mr. Rainville brings over two decades of healthcare marketing, operations, commercialization, and brand development experience and will be tasked with expanding the reach of the Bigfoot Unity Program. During his time at Lilly, Mr. Rainville served as a member of the Diabetes Youth Foundation of Indiana.
“I’m honored to accept this role at a watershed moment for Bigfoot, as we build momentum and work to transform the management of multiple daily injections (MDI) of insulin,” said Rainville. “We have a differentiated product, a skilled team and a community of patients who need solutions for insulin management. My focus is on expanding access to these solutions for people on MDI therapy.”
Rainville is poised to help Bigfoot as it continues to expand access to its Bigfoot Unity Diabetes Management Program, which began commercialization in 2021. With Bigfoot Unity, the company has reimagined how clinicians treat and manage their patients with Type 1 or Type 2 diabetes who rely on multiple daily injection insulin therapy with innovative smart pen cap technologies and remote-care solutions.
About Bigfoot Biomedical, Inc.
Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes. We seek to change the paradigm of care for diabetes. Bigfoot is an unconventional company taking an unconventional approach. Unlike others, we’re looking at insulin therapy holistically and utilizing services, support, and novel business models. We’re partnering with health care providers to deliver simple, connected, and comprehensive solutions for the large number of people who have been overlooked by diabetes innovation. Learn more at www.bigfootbiomedical.com. Follow us @BigfootBiomed on LinkedIn, Twitter, Instagram, and Facebook.